Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

AltaRex reacquires Western European marketing rights to Ovarex

Jan. 27, 1998

New approach to cancer therapy reported

Jan. 27, 1998

Vical receives patent protection for lipid-mediated DNA vaccines

Jan. 8, 1998

Mechanism of TNF-alpha production in tumor tissues by Ono-4007

Jan. 5, 1998

Favorable phase III trial results reported for HER2 monoclonal antibody

Dec. 31, 1997

Chiron's Proleukin recommended for approval for new indication

Dec. 23, 1997

New antitumor agent in development in China

Dec. 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...